Development, validation and clinical implementation of cellular swab materials for quality assurance of pharmacogenomic point-of-care testing

Background: Pharmacogenomic point-of-care testing (PGx POCT) enables genotype-informed prescribing at the bedside, but implementation is limited by the lack of suitable reference materials and standardised external quality assessment (EQA). Methods: Fixed lymphoblastoid cell lines were formulated as swab-based materials at defined cellular inputs for MTRNR1 POCT. Materials were evaluated using Genedrive MTRNR1 assays, quantitative PCR, acceptance quality limit batch release, workflow perturbation testing and stability studies, then deployed in an international EQA programme. Results: Materials

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.